medihemp

  • All our CBD products are made of EU certified industrial hemp plants.
  • Our industrial hemp grows on our own fields in the sunniest part of Austria.
  • All fields are certified organic, no pesticides, herbicides and fertilizers are used.

Our products are 100% natural!
We are convinced that the chemical balance of the plant should be respected, and that an isolated cannabinoid can never achieve the effect created by the interplay of all the cannabinoids. In our new CO2 oils and in the extract the other cannabinoids are present in higher concentrations.

CBDa and CBD
Our hemp flowers are intentionally not heated during processing, but purely naturally produced. As a result, the concentrated hemp extract provides unique components because it contains both CBD (cannabidiol) and CBDa (cannabidiol in a carboxylic acid form). Both forms have been found in many studies to be very effective. CBD is obtained by Decarboxilation (heating) of CBDa on min. 145 ° C.

Cannabinoides und Terpenes
In addition to the CBD and CBDa our new CO2 extract also contains other phyto-cannabinoids such as CBC, CBG, CBN, CBV, terpenes, flavonoids and penoles.

The most common terpenes in our CBD products
Myrcen, Limonene, Alpha & Beta-Pinen Linalool, B-Caryophyllen, Caryophylleenoxide, Humulen, Nerolidol und Phytol.

Use and durability
Shake well before use. Stability: Refer to the recommended storage up to 1 year.

Storage
On a cool and dark place (refrigerator). Durability at recommended storage: 1 year. Keep away from children.

Quality
Non-GMO organically grown plants (not genetically modified foods) Regular HPLM (High Pressure Liquid Chromatography) analyzes by the Seibersdorf Laboratories, Austria.

bio garantie

Controlled by Austria Bio Garantie
Disclaimer: Do not use if pregnant or breastfeeding. These statements have not been evaluated by the Food and Drug Administration. Consult always a doctor before using a new product.

Find out more about the use of CBD-rich cannabis sativa
Our CBD oils and liquids are the most natural available CBD products on the market. For your Info: In Austria and the EU, the active ingredient CBD cannabis plant is not regulated. ONLY the psychoactive (and therefore illegal) THC from a value of 0.2% (0.3% in Austria, 1% in Switzerland) is prohibited. Therefore, you can purchase all other cannabinoids legal. Cannabinoids take in ANY form (solid, liquid, highly concentrated, less concentrated) the same effect. They fight not only cancer cells but have positive effects on all human systems (immune system, digestive system, reproductive system, cardiovascular system).

What is CBD? - Cannabidiol (CBD) at a glance
Cannabidiol (CBD) is a compound in the cannabis plant, which has significant medicinal effects, but no psychoactive effects as that of the Cannabinoid THC. Therefore, CBD-rich cannabis varieties and products that contain only CBD / CBDa are now for many patients an attractive form of treatment. The Cannabinoid Cannabidiol (CBD) has analgesic, anti-inflammatory, anti-psychotic and anti-spasmodic effects and has been used successfully for pain, anxiety and for the relief of psychotic symptoms.

Medihemp CBD products are the extracted Cannabinoids from the dried, EU certified hemp plants. CBD, CBDa and other Cannabinoids have i.a. a calming effect on the body and the mind of people and animals. Current research and clinical studies highlight the potential of CBD and CBDa as a treatment for a variety of diseases and disorders, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, and antibiotic-resistant infections, epilepsy and other neurological diseases.

CBD has a neuroprotective and neurogenic action and its anti-cancer properties are currently under investigation in several academic research centers in the US, Israel and other countries. There have already been several scientific evidence found, that CBD and CBDa can help to fight cancer cells and suppress cell growth of cancer cells. A large number of patients are interested in the medicinal benefits of CBD and CBDa and set this as a Cannabinoid effective treatment for certain symptoms and diseases. After decades, the focus was primarily on THC-rich cannabis strains with strong psychoactive effects, now more and more varieties of cannabis with higher CBD levels and only minor amounts of THC are bred specifically intended for medical use.

How Cannabinoids destroy cancer cells
The human body constantly produces cancer cells that are destroyed by the immune system. If the immune system can no longer keep them at bay, cancer cells growing up to be a tumor. In each cell there is a family of interchangeable sphingolipids, which governs the life and death of a cell. These lipids regulate the production of ceramide, a metabolite that induces a very high concentration of cell death. A very small ceramide level means that a cell is strong and vigorous. The role of ceramide is to corrupt and destroy dying cells. When a a cancer cell grows, at the same time increases the production of cannabinoid receptors in this cell. Now, if the immune system "see" this, the endocannabinoid system (part of the immune system) reacts with the production of ceramide.

Ceramide attacks the mitochondria (energy producer of the cell) of the cancer cell and destroys it. Without mitochondria eventually dies also the cancer cell. If it happens that our immune system is weakened (by illness, stress, etc.), it can no longer control the continuous regulation of cancer cells by a ceramide-production and the cancer cells can grow freely. This lack of ceramide-production can be countered now with the supply of Cannabinoids (THC & CBD). The Cannabinoids dock at the Cannabinoid receptors of the cancer cell and signal the body that the cell is damaged, resulting in a massive production of ceramide. The DNA of a cancer cell is damaged in itself and disturbed. When the ceramide register this disorder, it migrates to the cancer cells and destroys their mitochondria.

Anti-tumor effect of Cannabinoids
The anti-tumor effect of Cannabinoids is biochemically demonstrated: Cannabinoid receptors are the most common receptors in the human body and brain. Humans are genetically programmed to accept Cannabinoids, it is completely natural.

Proper dosage
The correct dosage of CBD and CBDa is not an easy task. Historically, it has been many years even leave the patient to find out the dosages and to determine. 2004, a scientific article by Donald Abrams, MD, Professor of Clinical Medicine was published at UC San Francisco, stating that "the dose may be determined by the patients themselves, in which the dose gradually increased, or is changed. Due to the low toxicity and the impossibility of an overdose of gradual convergence towards the correct dosage is a great way to find the effect you want to achieve individually. Start with 3 drops daily in the evening and each increase by one drop, and later several times a day. "

Article by Dr. Franjo Grotenhermen
How does cannabis in the brain? How can the many uses of cannabis in a variety of diseases explain? The following article by Dr. med. Franjo Grotenhermen of the Nova-Institut (Hürth in the Rhineland), who is also the author of "Cannabis as Medicine", take a position and provides a detailed explanation. The endocannabinoid system - function and significance for therapy For more than ten years, it is known that THC - the main psychoactive ingredient in cannabis - exerts most of its effect on specific binding sites on the cells of the organism. Later substances have been discovered that are produced by the body and THC - have comparable effects on these receptors. Gradually, the knowledge enlarged beyond the natural function of these endocannabinoids. This understanding can on the one hand the medical benefits of hemp (Cannabis sativa L.) explain and on the other hand lead in the near future to develop completely new drugs. 1987 at cannabis Congress in Melbourne (Canada) demonstrated Professor Allyn Howlett of the Saint Louis University in Missouri (USA) for the first time that some of the cannabinoid receptor-mediated effects.

This means that they come across a bond of cannabinoids bind to specific binding sites on cells of the body about. These binding sites are called cannabinoid receptors. It opened up a new field of research in which there almost every year were new important discoveries in the last decade and will certainly be even more that improve our understanding of the effects of the hemp plant as well as present new perspectives for the treatment of diseases. With about 350,000 Mark alone the British Heart Foundation supports research into the effect of endocannabinoids on the circuit. Professor Brian Pentecost, medical director of the British Heart Foundation, said: "These are natural substances that occur anywhere on the body, and they seem to have important effects on the circulatory We hope that this project will bring new insights into how we this. effects can be used to help heart patients (PA NEWS December 29, 1998) Cannabinoid receptors

Cannabinoid receptors are located in the cell membrane (the envelope) cells of different cell types and protrude with one part at the surface of the cell and another into the cell. Now binds THC (delta-9-tetrahydrocannabinol) or other substance that fits like a key in this castle, to this receptor, so changed that. This change triggers certain processes in the so-activated cells. In the case of cannabinoid receptors, these are, for example, changes in cell membrane permeability for potassium and calcium, as well as effects on protein, adenylate cyclase, put the other processes in the cell in transition. The human body has to stabilize its complex body functions, a range of receptors for substances such as adrenaline, estrogen, endorphins and many other endogenous substances. Many cells have receptors for various substances such binding. There are often, as in the case of the cannabinoid receptors, several subtypes of receptors.

In the cannabinoid receptors is called CB1 receptors, mainly in the central nervous system (brain, spinal cord) are found and CB2 receptors. For several months, a further subtype is suspected, the will may be mentioned CB3 receptor (Zygmunt 1999). Like other receptors and can either be enabled or blocked cannabinoid receptors by docking of certain substances. Some of these substances dock almost exclusively at the CB1 receptors, while others bind specifically to the CB2 receptor, in turn, others, such as THC, bind to both the CB1 and CB2 and the receptor. Endocannabinoids With the discovery of cannabinoid receptors was clear: if there are these receptors, they also have a natural function of the body and there must be endogenous substances that activate this receptor.

These endogenous substances that bind to cannabinoid receptors, endocannabinoids are called. The research group of Professor Raphael Mechoulam of the Hebrew University in Jerusalem, the first endocannabinoid proved in 1992, it called anandamide, after the Sanskrit word Ananda, the bliss is, and its chemical structure, the amide. Of these natural amides that bind to cannabinoid receptors have been further discovered, including the palmitylethanolamide. 1995 endocannabinoid a new type has been demonstrated that 2-arachidonoylglycerol. The duration of action of the previously known endocannabinoids is in the range of a few minutes, is thus considerably shorter than those of the plant cannabinoids. They are apparently released by the body cells in the immediate vicinity of their site of action of certain enzymes and degraded relatively rapidly back into inactive substances or reintroduced into the cells.

Function of the endocannabinoid system
Already the distribution of cannabinoid receptors and endocannabinoids may be prudent to draw conclusions about their natural function. As already mentioned, CB1 receptors are found primarily on nerve cells in the brain and spinal cord. In a lower concentration CB1 receptors were also detected in some other tissues, such as in blood vessels, the heart, the testis, the spleen and parts of the gastro-intestinal tract. CB2 receptors, however, are found mainly on immune system cells such as white blood cells and appear to have a role to play like about inflammation in the modulation of immune functions. In contrast, the natural function via the CB1 receptors mediated effects seem to be very diverse, which are beginning to be elucidated. CB1 receptors are unevenly distributed in the brain and are particularly concentrated in areas of the brain, for example having a role in coordination of movements, processing of sensations of pain processing and memory. This is consistent with the known acute effects of marijuana as relaxation and change of muscle coordination, intensification of sensations, pain, change in mental processes, et cetera.

In the field of instrumentation of the blood vessels apparently the endocannabinoids affect the tension of the vessel wall and thus blood pressure. It is believed that endocannabinoid system play a role in blood pressure drop in septic shock plays (Varga 1998). Substances that activate the cannabinoid receptor could find in the treatment of high blood pressure application, possibly. Professor Michael Walker from Brown University in Providence, Rhode Iceland (USA) deals with a function of endocannabinoids in pain processing. He was able to show that in the initiation of a pain stimulus in certain areas of the brain increased anandamide is released and that this release soothed the pain (Walker, 1999) recently. Walker said that one could possibly develop a drug dasdie anandamide increased concentration to treat certain pain conditions better.

The Endocannabionidsystem interacts with other receptor systems. Researchers at the University of California at Irvine have demonstrated interactions between the endocannabinoid and dopamine neurotransmitter system in an area of the brain called the striatum (Giuffrida 1999). Deviations from the normal function of this region of the brain are associated with diseases such as Parkinson's disease and Tourette syndrome. The experiments carried out suggest that a natural function of anandamide is to counter excessive stimulation of the dopamine system and thus to a strong activation of the muscles. This hypothesis is in Übereinstummung with the successful use of cannabis by patients who suffer from bestimment movement disorders. In schizophrenics an increased endocannabinoid concentration was detected in the cerebrospinal fluid (Leweke 1999).

One explanation for the approximately twice as high concentration in schizophrenics in pared with healthy is here also an attempt by the brain to compensate for a hyperactive dopamine system. This could erklören why many schizophrenics smoke marijuana. It could be that patients try to self-medicate. Other nerve transmitter substances whose release ds in bestimten brain areas are inhibited by endocannabinoids, are acetylcholine, noradrenaline, 5-hydroxytryptamine, gamma-aminobutyric acid, glutamine and D-aspartate. These interactions may be able to determine explain known effects of marijuana. 5-hydroxytryptamine, for example, plays a role in vomiting and the most effective antiemetic agents used today in medicine are antagonists of 5-hydroxytryptamine.

Influence of endocannabinoids In addition to the direct activation or blocking cannabinoid receptors by externally applied substances have already succeeded in experimentally today to influence the concentration of Endocannabionide and so activate the cannabinoid receptors indirectly. Thus, it would be conceivable in the future to perform a pain therapy in this manner by increasing the concentration of anandamide. There are two possibilities, the inhibition of the degradation of endocannabinoids or inhibiting the reuptake of endocannabinoids in the cells. Indeed, substances already have been developed which can affect the Endocannabionide in this manner.

Perspective for medicine These findings have implications for the development of new drugs. In addition to natural cannabis and cannabinoids are natural individual a number of substances that affect different way what is happening to cannabinoid receptors and the concentration of endocannabinoids, are tested for their therapeutic benefits and tested in the future. It is therefore to be expected with a number of new drugs based on the study of the endocannabinoid system. Basically, the following approaches can be followed: 1. The already successful approach followed is the gift of natural or synthetic cannabinoids that activate cannabinoid receptors. Here is yet to be explored, such as the compatibility could be further improved. For example, it is known that the psychological effects of THC by cannabidiol be reduced so that a combination could about in a natural cannabis preparation improve Verträglchkeit.

There is also evidence that cannabis can be usefully combined with some other drugs and complement the effects of each other. , You may also synthetic cannabinoids are developed that specifically act outside the brain, because it does not penetrate the blood-brain barrier. 2. The concentration of endocannabinoids could be influenced by substances that affect their degradation or their re-uptake into cells. The advantage of this approach with respect to the supply of cannabinoids could bebstehen that they mainly act where a particularly strong endocannabinoid production already exists, this research is still in the experimental stage. 3. There may be allowed (or cannabinoid receptor antagonists) use therapeutically cannabinoid receptor blockers. Since cannabinoids can acutely impair memory or cause distress, a use in memory or Anstzuständen would be conceivable. Antagonists inhibit the action of endocannabinoids.

Receptor-independent effects 
1. The effects of the natural appear across the hemp plant Cannabidiols (CBD) are non-receptor-mediated. CBD counteracts the psychological effects of THC. A Brazilian research group led by Professor Antonia Zuardi of the University of Sao Paulo showed that high doses of cannabidiol as well as the strong neuroleptic Hloperidol participated in a schizophrenic in an acute psychosis without cause relevant side effects (Zuardi, 1997)

2. Different cannabinoids, including THC and CBD, have neuroprotective effects in case of a lack of nerve supply with oxygen or other Mangelversogrungszuständen on (Hampson, 1998). Such lack of supplies occur for example when Schalganfall at a carbon monoxide poisoning or head injury. They trigger chemical reactions over, including excessive Ausschuüttung excitation of the nervous substance glutamate, the formation of free radicals and inflammation. Cannabinoids weakened in cell experiments from all this poison own effects. Be particularly effective, a non-psychotropic cannabinoid syntehtisches, the Dexanabinol has proven that is already erpropt in clinical studies in humans (Mechoulam 1999).

3. Only a few years ago, it was found that certain Abbaupordukte of cannabinoids exert anti-inflammatory and analgesic effects. This not psychologically wirksameen cannabinoid acids, had been a long time no attention. Recently, bnimmt it is believed that they contribute to the overall therapeutic effect of natural cannabinoids. Particularly intense a synthetic derivative of THC degradation product is currently investigated, the CT-3 (dimethylheptyl THC-11-carboxylic acid) which has been shown in animal studies show good activity in Gelenkentzündugen or arthritis (Zurier 1998)

CBD olie Groothandel

Waar vind ik betrouwbare informatie over CBD?

Literature:
1. Giuffrida, A., et al.: Nat. Neurosci.2, 358-363 (1999)
2. Hampson, A.J., et al.: Proc. Natl. Acad. Sci. USA 95, 8268-8273 (1998)
3. Leweke, F.W., et al.: NeuroReport 10, 1665-1669 (1999).
4. Mechoulam, R.: In: Grotenhermen, F., Saller, R. (Hrsg.): Cannabis und Cannabinoide in der Medizin Forschende Komplementärmedizin, im Druck (1999)
5. Varga, K.; et al.: FASEB J. 12, 1035-1044 (1998).
6. Walker, M., et al.: Proc. Nat. Acad. Sci., zitiert nach Reuters vom 11. Oktober 1999
7. Zuardi, A.W., Guimaräes, F.S.: In Mathre, M.L. (Hrsg.): Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. McFarland&Co., Jefferson, NC. 1997; S.133-141
8. Zurier, R.B., et al.: Arthritis Rheum. 41, 163-170 (1998) 9. Zygmunt, P.M., et al.: Nature 400, 452-457 (1999)